SCHEMBL5795313

SCHEMBL5795313

O=C(O)Cc1cccc(S(=O)(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)c1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
ALDH1A1 P00352 3/20 0.69
KDM4E B2RXH2 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
CYP3A4 P08684 3/20 0.52
USP2 O75604 2/20 0.52
CYP2C9 P11712 2/20 0.52
MAOA P21397 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
CYP3A5 P20815 1/20 0.48
CYP2D6 P10635 1/20 0.48
ATM Q13315 1/20 0.48
PKM P14618 2/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.45
HDAC1 Q13547 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925079 0.94 MEN1 (0.64) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL5745578 0.91 KMT2A (0.57) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3927929 0.89 GAA (0.56) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3930627 0.87 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3929081 0.87 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3925084 0.83 CYP3A4 (0.53) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3928702 0.83 CYP3A4 (0.57) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3932017 0.83 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL3933976 0.82 MEN1 (0.58) MEN1KMT2AALDH1A1KDM4ETDP1
SCHEMBL6357532 0.81 HTT (0.58) MEN1KMT2AALDH1A1TDP1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD MEN1 4791/4885KMT2A 2378/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.